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Abstract 
 Ataxia Telangiectasia (A-T) patients exhibit several clinical pathologies, including Type- 
2 Diabetes. Several factors, such as increased Reactive Oxygen Species (ROS) levels, increased 
inflammatory signaling have been proposed to account for insulin resistance in Type 2 Diabetes. 
However, the major factors that contribute to insulin resistance in A-T patients due to the 
disruption of the ATM-p53 signaling pathway are still unclear. In this project, the mouse model 
p53Ser23Ala in which the p53 phosphorylation site at Serine 23 was mutated exhibited insulin 
resistance. The expression of p53-dependent antioxidant genes (Sestrin 1, 2 and 3) in the 
fibroblasts of the p53Ser23Ala mice was found to be significantly decreased, indicating the 
potential for increased oxidative stress. As p53 is the key downstream effector in the disrupted 
ATM-p53 signaling pathway, these data have implicated that p53 phosphorylation sites at Ser23 
plays an important role in insulin resistance by regulating the expression of Sestrin genes.   
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Background 
Diabetes  
Diabetes is a metabolic disease characterized by abnormally high blood glucose levels or 
hyperglycemia. As insulin is required to transport glucose from the bloodstream into the cells to 
produce energy, diabetes could result from the absence of insulin production by the pancreas or 
defects in insulin signaling pathway or both. There are two major types of diabetes: type 1 and 
type 2.  In type 1 diabetes, the β cells of pancreas, which are responsible for insulin production, 
are mistakenly attacked by the body’s immune system. The pancreas, therefore, could not 
produce insulin, leading to the state of hyperglycemia. In type 2 diabetes, the body does not 
respond to insulin properly, which is defined as insulin resistance. As a result, the pancreas has 
to produce extra insulin to make up for this defect at first. However, over time, the pancreas 
cannot keep up with it, causing insulin insufficiency (American Diabetes Association, 2014). 
When glucose accumulates in the bloodstream instead of being transported to the cells, the cells 
are starved for energy. Over time, high blood glucose levels cause damage to different parts of 
the body including the eyes, kidneys, nerves and heart (American Diabetes Association, 2014). 
Type 2 diabetes is the most common form of diabetes, being responsible for 90%- 95% of 
diabetes cases in the United States (Centers for Disease Control and Prevention, 2014). Though it 
is still not fully understood why some people develop insulin resistance, it has been found that 
obesity is the primary risk factor for type 2 diabetes. The cells are more likely to become insulin 
resistant when one has more fatty tissue (Mayo Clinic, 2013). In addition, certain groups, such as 
African Americans, Latinos, Native Americans, Asian Americans/Pacific Islanders as well as the 
aged population have higher risk for Type 2 diabetes than other groups (American Diabetes 
Association, 2013).  
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Insulin signaling pathway 
The primary role of insulin is to increase the uptake of glucose in muscle and fat tissue.  
Insulin can also induce the uptake of fatty acids into adipose tissue and muscle.  Insulin increases 
glycogen synthesis, which is the storage of glucose as glycogen in liver and muscle. The primary 
role of insulin in the liver is to suppress hepatic gluconeogenesis, the production of glucose from 
non-sugar substrates. Figure 1 below presents how the insulin signaling pathway regulates the 
uptake of glucose. 
 
 
Figure 1: Insulin signal transduction pathway (Schwartz et al., 2013) 
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Regulation of glucose uptake and storage:  
The insulin receptor consists of two extracellular α subunits and two transmembrane β 
subunits linked by disulphide bonds. When insulin binds to the α subunit of the receptor, a 
number of tyrosine residues in the β subunit undergo autophosphorylation and are then 
recognized by members of insulin receptor substrate (IRS) family (Figure 1) (Van Obberghen et 
al., 2001, Saltiel and Kahn, 2001, Lizcano and Alessi, 2002, Hooper, n.d). As seen in Figure 1, 
the signal is then relayed by the binding of the regulatory subunit of PI3K to phosphorylated key 
tyrosine residues on IRS proteins and the phosphorylation of phosphatidylinositol (4,5) 
bisphosphate (PI(4,5)P2) to PI(3,4,5)P3. One key downstream effector of PI(3,4,5)P3 is AKT, 
which, once activated, induces glycogen synthesis through inhibition of GSK-3 and promotes 
glucose storage through translocation of glucose transporter GLUT4 to the plasma membrane 
(Lizcano and Alessi, 2002; Saltiel and Kahn, 2001, Hooper, n.d ). In addition to inducing glucose 
storage, insulin inhibits the production and release of glucose by the liver by blocking 
gluconeogenesis and glycogenolysis, which also involves AKT (Saltiel and Kahn, 2001, Hooper, 
n.d).  
Regulation of lipid synthesis: 
In addition to maintain glucose homeostasis, insulin plays an important role in the uptake 
of fatty acids and the synthesis of lipid. It has been found that the transcription factor steroid 
regulatory element-binding protein is upregulated in lipid synthesis (SREBP)-1c (Shimomura et 
al., 1999; Saltiel and Kahn, 2001, Hooper, n.d). However, the pathway of how insulin regulates 
SREBP-1c expression is still unknown. While promoting lipid storage, insulin also inhibits lipid 
metabolism through decreasing cellular concentrations of cAMP by activating a cAMP specific 
phosphodiesterase in adipocytes (Kitamura et al., 1999, Saltiel and Kahn, 2001, Hooper, n.d). 
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Regulation of protein synthesis: 
Likewise, insulin triggers amino acid uptake into cells, inhibits protein degradation and 
promotes protein synthesis (Saltiel and Kahn, 2001, Hooper, n.d).  Once active, AKT activates 
mTOR and inactivates GSK-3, leading to the dephosphorylation and activation of eIF2B, both of 
which promote protein synthesis and the storage of amino acids (Lizcano and Alessi, 2002, 
Asnaghi et al., 2004, Hooper, n.d). 
Underlying Mechanisms 
Many defects in the insulin signaling pathway have been proposed as the underlying 
mechanisms of insulin resistance (Saltiel and Kahn, 2001). As tyrosine phosphorylation of IRS is 
a key process in insulin signaling, it has been suggested that the decrease in tyrosine 
phosphorylation of IRS family members in a potential mechanism for insulin resistance (Morino 
et al., 2006; Zick, 2005). The activation of serine/threonine kinases that phosphorylate of IRS 
proteins at serine residues prevents the binding of IRS proteins with the insulin receptor, 
consequently decreasing the activation of PI3K (Zick, 2005). Activation of such kinases could be 
the consequence of increased pro-inflammatory signaling caused by excess circulating free fatty 
acids (FFAs). IκB kinase (IKK) and c-Jun N-terminal kinase (JNK), which phosphorylate IRS-1 
at serine residues, are then activated and cause damage to the insulin signaling pathway. 
Increased circulating FFAs also trigger the production of cytokines, including tumor necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) (Shi et al., 2006; Kim et al., 2007; 
Senn et al., 2006). The activation of serine kinases like IKK and JNK could also be attributed to 
endoplasmic reticulum (ER) stress (Kim et al., 2008) and excess reactive oxygen stress (ROS) 
caused by mitochondrial dysfunction (Nishikawa, 2007).  
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Ataxia Telangiectasia (A-T) Patients and Insulin Resistance 
Ataxia Telangiectasia (A-T) is a rare, recessive genetic disorder caused by mutations in 
A-T mutated (ATM) gene. A-T is characterized by progressive cerebellar ataxia, telangiectasias, 
immunodeficiency with susceptibility to sinus and respiratory infections, and a high risk of 
cancer (Jozwiak et al., 2012). Normally, protein kinase ATM phosphorylates several critical 
substrates for DNA repair and cell cycle control in response to DNA damage. Though less 
common, about 25% of A-T patients are also diagnosed with insulin resistance, showing 
defective glucose homeostasis (Miles et al., 2007). Thus, this clinical phenotype represents a 
potential connection between tumor suppressor pathway and glucose homeostasis. Recent work 
by the Sluss lab has demonstrated in vivo that mice deficient in ATM and an ATM 
phosphorylation site on p53 develop insulin resistance (Armata et al., 2010). 
An emerging role of p53 tumor suppressor and ATM/p53 signaling pathway 
Encoded by the TP53 gene, the p53 tumor suppressor protein is potent a transcription 
factor that plays a critical role in the protection against tumor formation. Under normal 
conditions, p53 tumor suppressor is found at extremely low levels (Goodsell, 1999). However, 
when DNA damage is sensed, p53 levels rise and initiate protective processes by inducing cell 
cycle arrest mostly at G1 checkpoint, thus isolating the damaged genome. Also, p53 can trigger 
apoptosis to further remove the DNA damage (Goodsell, 1999). About 50% of all cases of 
human cancer can be attributed to mutations in p53 tumor suppressor. Such mutations abrogate 
the protective role of p53, thus facilitating carcinogenesis (Oren, 1999).  
The p53 tumor suppressor, composed of four identical protein chains, can be divided into 
seven domains: the activation domain 1 or trans-activation domain at the N- terminus, the 
activation domain 2, the proline-rich domain, the site-specific DNA-binding domain, the nuclear 
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localization domain, the tetramerization domain, and the C-terminus involving the 
downregulation of DNA binding of the central domain (Figure 2) (Appella and Anderson, 2001). 
Many phosphorylation sites in p53 have been identified and it has been suggested that specific 
phosphorylation events are responsible for specific functions of p53. In A-T disorder, ATM that 
is normally activated when sensing DNA strand breaks caused by ionizing radiation, is mutated. 
As the ATM/p53 signaling pathway is disrupted, ATM cannot directly phosphorylate p53 
directly at Serine 18 residue in mouse (Serine 15 residue in human) or activate Chk2 to 
phosphorylate p53 at Serine 23 residue in mouse (Serine 20 residue in human) to induce cell 
cycle arrest and apoptosis (Figure 2).   
 
Figure 2: DNA damage-induced post-translational modifications to human p53 (Appella and 
Anderson, 2001) 
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In addition to its traditional role as a DNA damage sensor, ATM has been shown to play 
an important role in metabolic and cardiovascular diseases. Several studies have demonstrated 
that ATM could inhibit JNK, thus improving insulin sensitivity and cardiovascular effects 
(Shoelson, 2006). Also, there is a lot of growing evidence showing that p53 is an important 
regulator of metabolic pathways (Maddocks and Vousden, 2011). For example, as seen in Figure 
3, p53 has been found to influence glycolysis by upregulating the expression of glucose 
transporter 1 and 4 (GLUT1, GLUT4), TP53-induced glycolysis and apoptosis regulator 
(TIGAR), and downregulating the expression of phosphoglycerate mutase (PGM) (Puzio-Kuter, 
2011). Therefore, it is proposed that disrupted ATM-mediated phosphorylation sites of p53 in A-
T patients could be related to their development of insulin resistance.  
 
Figure 3: The role of p53 in regulating energy metabolism: glycolysis and oxidative 
phosphorylation (Puzio-Kuter, 2011) 
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 Sluss Lab Studies on the role of ATM-mediated Phosphorylation Sites in Insulin 
Resistance 
Therefore, it is proposed that disrupted ATM-mediated phosphorylation sites of p53 in  
A-T patients could be related to their development of insulin resistance. 
p53Ser18Ala mouse model:  
It has been previously found in Sluss Laboratory that ATM-mediated Serine 18 
phosphorylation site is required to maintain glucose homeostasis (Armata et al., 2010). A mouse 
model in which the p53 Serine 18 phosphorylation site in the trans-activation domain of p53 was 
replaced with Alanine (p53Ser18Ala) was used for the study. These mice were found to exhibit 
glucose intolerance and insulin resistance. Increased oxidative stress due to the downregulation 
of antioxidant gene expression was proposed to be the major contributor to the defective glucose 
homeostasis in p53Ser18Ala mice, as insulin sensitivity was restored with antioxidant treatment. 
Thus, it can be concluded that p53 Serine 18 phosphorylation plays a protective role against 
insulin resistance.  
p53Ser23Ala mouse model:  
In order to further define the role of p53 tumor suppressor pathway in glucose 
homeostasis, the Serine 23 phosphorylation site will be studied. Thus, a mouse model in which 
the Serine 23 residue in the trans-activation domain of p53 was replaced with Alanine was 
created (MacPherson et al., 2004). Mice on a regular chow diet were analyzed. Previous 
unpublished data from Sluss Lab have demonstrated that through a glucose tolerance test (GTT) 
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and Insulin tolerance test that these mice also develop insulin as presented in Figure 4 and 5 
below 
 
Figure 4: Glucose tolerance test (GTT). Mice fasted overnight were treated with glucose (1g/kg) 
by intraperitoneal injection. Blood glucose concentration was measured at the indicated times. 
 
Figure 5: Insulin Tolerance Test (ITT). Mice fasted overnight were treated with insulin 
(0.75U/kg) by intraperitoneal injection. Blood glucose concentration was measured at the 
indicated times. 
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In this project, several factors including the expression of antioxidant genes and 
inflammatory genes will be examined to determine the significant factor contributing to insulin 
resistance in p53Ser23Ala mice. Also, AKT, one key downstream effector in the insulin 
signaling pathway in fibroblasts, liver and muscle tissues will be examined as evidence for 
disruption of this pathway. It is hypothesized that the disruption of ATM pathway would lead to 
the downregulation of antioxidant genes and upregulation of pro-inflammatory genes in mutant 
p53Ser23Ala mice, as excessive oxidative stress and increase in activation of inflammation 
signaling are proposed mechanisms for insulin resistance in Type-2 Diabetes.   
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Materials and Methods 
Tissue Culture  
Primary murine embryo fibroblasts (MEFs) were prepared from wild-type and p53S23A 
embryos. The MEFs were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, #11965-
118) supplemented with 10% Fetal Bovine Serum (Thermo Scientific, SH30396.03), Antibiotic 
(Invitrogen, #15140-122) and Glutamax (Invitrogen, #35050-061). MEFs were at passage 2 for 
insulin response experiment. For insulin response analysis, cells were starved 15 to 18 h in 
Dulbecco’s glucose free media (Invitrogen, #11966). Cells were then treated with insulin 
(Sigma, #I0516, Insulin Bovine Pancreas, 10 mg/mL) and harvested at the indicated time points 
including 0, 30 minute, 1 hour and 4 hour. The cell pellets were stored at -80oC for Immunoblot 
Analysis.  
Quantitative Real time PCR  
RNA Purification  
Total RNA was prepared with RNeasy Mini kits (Qiagen, #74104) by following the 
manufacturer’s instructions. The first and second elution RNA concentrations were measured 
using Thermo Nanodrop 2000 Spectrophotometer. Purified RNA samples were frozen on dry ice 
and stored at -80oC.  
RNA Clean up 
The purified RNA was subjected to an additional DNase treatment to remove 
contaminating genomic DNA prior to final column purification by RNeasy Mini kit. 20 μg of the 
purified RNA and nuclease-free water, in a total volume of 80 μl were added to 20 μl of a mix 
consisting of 2 μl DNAse, 10 μl 10X DNase I Buffer and 8 μl of nuclease-free water from the 
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DNA-free kit (Ambion, #AM1906). The samples were incubated for 20 minutes at 37oC, and 
then an additional 1 μl of DNase from the kit was added to each sample. The samples were 
incubated for another 20 minutes at 37oC, and then 10 μl of the DNase Inactivation Reagent from 
the kit was added to each sample and mixed for 2 minutes at room temperature. The samples 
were spun at max speed 13000 rpm for 2 minutes, and the supernatant was transferred to a new 
tube. The instructions of RNeasy Mini kit were followed again. Cleaned RNA samples were 
measured again using Thermo Nanodrop 2000 Spectrophotometer and stored at -80oC.  
cDNA synthesis  
cDNA was prepared using iScript Reverse Transcription Supermix (Biorad, #170-8841) 
with 0.5 μg to 1 μg of RNA per tissue, following the manufacturer’s instructions for First Strand 
Synthesis. cDNA samples were stored at -20oC.  
Quantitative Real-Time PCR 
Quantitative Real-Time PCR was performed on a Bio-Rad iCycler using Sybr green 
master mix (Bio-Rad). The primer sequences for the murine genes were as follows: Gapdh (5-
CTTCACCACCATGGAGAAGGC-3, 5-GGCATGGACTGTGGTCAT-3), Sesn1 (5- 
GGCCAGGACGAGGAACTTG-3, 5- AAGGAGTCTGCAAATAACGCAT-3), Sesn2 (5- 
TCCGAGTGCCATTCCGAGAT-3, 5- TCCGGGTGTAGACCCATCAC-3), Sesn3 (5- 
GCGAGGAGAAGAACATTTGCC-3, 5- CCAAACATACAGTGAACATAGT-3), mTNF (5-
ACAGAAAGCATGATCCGCG-3, 5-CTGGGCCATAGAACTGATG-3), mIL6 (5-
AAGAGACTTCCATCCAGTTGC-3, 5-CTCCGACTTGTGAAGTGGTAT-3), mIL1(5-
AAAGCTCTCCACCTCAATGG-3, 5-TCTTCTTTGGGTATTGCTTGG-3), mGhrl (5- 
GCTGTCTTCAGGCACCATCT-3, 5- GTGGCTTCTTGGATTCCTTTC-3). All samples were 
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examined in triplicate, and values were normalized for baseline expression and for expression of 
Gapdh. Calculations of values were made using the ΔΔCT method. Statistical significance was 
calculated using threshold cycle (CT) values. 
Immunoblots 
Preparation of Protein Lysates:  
Animal tissues and MEF pellets were lysed in 1X TLB Lysis Buffer (2X Triton Buffer, 
50% Glycerol, Water, 1M β-glycerophosphate, 100 mM Sodium Orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, 5 mg /mL Aprotinin and 10 mg/mL Leupeptin). Protein samples 
were snap-frozen into liquid nitrogen and stored at -80oC.  
BCA Protein Assay 
Protein samples and standards were prepared using BCA Protein Assay Kit (Pierce, 
#23225) following the manufacturer‘s instructions. In each well of a 96-well plate, 2 μl of the 
protein lysate sample was added to 23 μl of sterile water, then 200 μl of the working reagent was 
added to each well and then mixed. The plate was incubated at 37oC for 30 minutes and the 
absorbance was then read at 550 nm on a Thermo Multitask Ascent Plate Reader. The measured 
concentrations were then used to prepare loading samples for Western Blots. Each sample had 50 
μg-100 μg of protein in a total volume of 50 μl; 10 μl of Laemmli’s SDS-sample buffer (6X, 
reducing) was added to the appropriate amount of protein and mixed well. 1X TLB Lysis Buffer 
was added to the sample to bring the final volume to 50 μl.  
Immunoblot Analysis 
Protein lysate extracts from tissues and MEFs (50-100 μg) were analyzed by Immunoblot 
analysis using primary antibodies to RNa Protein extracts were run on 10% acrylamide gel with 
1X Running Buffer (10X Running Buffer, 10% SDS, and Water) and then transferred into 
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membrane using Transfer Buffer (10X Running Buffer, Methanol and Water). The membrane 
was blocked in 1X TBS-T 10% skim milk (10 mM Tris pH 8.0, 120 mM NaCl, 0.05% Tween 
20) for at least 1 hour. Then primary antibody (8 μl of the primary antibody in 8 mL of the 1X 
TBS-T 10% milk) was added to each membrane. The membrane was incubated overnight at 4oC. 
The membrane was washed three times with 10 minutes each time in 1X TBS-T and then 
incubated with secondary antibodies (1:20000 anti-mouse or anti-rabbit in 10% skim milk in 
TBS-T block solution) for one hour. The membrane was washed again three times with 10 
minutes each time in 1X TBS-T and then developed with chemilumenescene techniques.  
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Results 
ATM protein kinase is mutated in A-T patients, thus could not phosphorylate p53 at 
Serine 23 in mice in response to DNA damage by UV. Also, a number of A-T patients develop 
insulin resistance, suggesting a connection between the ATM signaling pathway and the insulin 
signaling pathway. The p53Ser23Ala mouse model with a mutation at ATM target 
phosphorylation site Serine 23 on the p53 protein in this project. The p53Ser23Ala mice were 
found to exhibit insulin resistance through GTT and ITT results, stressing the linkage between 
these two pathways. As excessive oxidative stress and increased pro-inflammatory signaling are 
proposed underlying mechanisms for insulin resistance, the role of these two factors will be 
examined using Real-Time PCR to analyze the relative expression of antioxidant genes and pro-
inflammatory genes in the fibroblasts and livers of wild-type and p53Ser23Ala. Additionally, the 
activation of the downstream effector AKT in the insulin signaling pathway in fibroblasts, liver 
and muscle tissue of wild-type and p53Ser23Ala mice will be investigated using Immunoblots to 
obtain evidence for insulin resistance in this mouse model.  
Expression of antioxidant genes and pro-inflammatory genes in wild-type and 
p53Ser23Ala mice  
In order to investigate whether antioxidant gene expression contributes to insulin 
resistance in p53Ser23Ala mice, the expression of such genes including Sestrin 1, 2 and 3, which 
are upregulated by the p53 protein upon DNA damage and oxidative stress (Budanov and Karin, 
2008), was examined by Real-Time PCR. As seen in Figure 6A, the levels of Sestrin gene 
expression in the fibroblasts of p53Ser23Ala mice were significantly reduced compared to those 
in wild-type mice, indicating a decrease in the antioxidant defense of the mutant mice. 
Additionally, inflammation has been proposed to play an important role in insulin resistance in 
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Type 2 Diabetes. Therefore, the relative expression of inflammatory cytokines, such as TNF-α, 
IL-6, IL-1 in MEFs and livers of wild type and p53Ser23Ala mice was also examined using 
Real-Time PCR. As shown in Figure 6B the relative expression of IL-6 was significantly greater 
in p53Ser12Ala MEFs.  Increased IL-6 expression indicates increased inflammatory signaling. 
Figure 7 showed significantly increased levels of IL-1 and increased expression of TNF-α and 
IL-6 in the livers of p53Ser23Ala mice. In addition, the gene expression of Ghrelin, a hormone 
that plays an important role in growth hormone secretion, appetite regulation and metabolism, 
was observed to be downregulated (Figure 6C), which has been reported to be associated with 
insulin resistance by several studies (Pöykkö et al., 2003, Dimaraki and Jaffe, 2006).  
Insulin Signaling Pathway  
From the GTT and ITT results, it has been found that p53Ser23Ala mice exhibited insulin 
resistance, suggesting defects in the insulin signaling pathway. Thus, in order to examine the 
insulin signaling pathway in these mutant mice and compare to that in the wild-type mice; the 
activation of AKT, one key downstream effector of the pathway was investigated in MEFs, liver 
and muscle tissue (Figure 8 and 9). Fibroblasts from wild-type mice and p53Ser23Ala mice were 
harvested at indicated time points after insulin treatment. Proteins were then extracted from the 
lysed fibroblasts. Similarly, extracts were obtained from the lysed liver and muscle tissues from 
wild type and p53Ser23Ala mice treated without and with insulin, and then examined by 
Immunoblot Analysis using anti-AKT, anti-pSer473 AKT, and anti-pThr308 AKT antibodies.  
In the first and second panel of Figure 8A, the band intensity of wild type MEFs 0.5 hour 
after the insulin treatment increased, indicating that AKT was phosphorylated at Ser473 and 
Thr308 correspondingly. After 1 hour, the band intensities of wild type MEFs were stronger, 
showing that more AKT was activated. After 4 hours, the bands of wild type MEFs faded as 
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insulin signaling was terminated. The band intensities of p53Ser23Ala MEFs also increased 0.5 
hour after the treatment. However, these bands were fainter than those of the wild-type MEFs, 
indicating that not as much AKT was activated. Also, the bands of p53Ser23Ala MEFs already 
faded at 1 hour after the treatment. The band intensities of p53Ser23Ala MEFs at 1 hour were 
shown to reduce compared to those of wild-type MEFs. The third panel demonstrates equal 
loading of AKT for both wild type and p53Ser23Ala fibroblasts. The quantification of 
Immunoblots for anti-pThr308 AKT as presented in Figure 8B demonstrated that the difference 
in the activation of AKT between wild-type and p53Ser23Ala MEFs 1 hour after the treatment 
was significantly greater compared to that of the control. 
In the upper panels of Figure 9A, in the absence of insulin, AKT was not activated for 
both wild type and p53Ser23Ala liver tissues. However, in response to insulin treatment, the 
signals for wild type tissues were stronger than those of p53Ser23Ala tissues, which also 
indicates insulin resistance in the liver tissue. Equal loading of AKT was shown in the lower 
panels. 
In contrast, there was no difference in AKT phosphorylation between the wild type and 
p53Ser23Ala muscle as shown in the upper and middle panels of Figure 9B. AKT was activated 
in the muscle of both genotypes in response to insulin. Likewise, equal loading of AKT was 
presented in the lower panels.  
Together, these results indicate the insulin signaling pathway in p53Ser23Ala MEFs and 
liver was impaired, but the muscle tissue of the mutant mice can still maintain the normal insulin 
sensitivity.  
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Discussion 
 Type 2 Diabetes is one of the clinical pathologies exhibited in some A-T patients. Several 
factors including increased ROS levels and increased inflammatory signaling have been believed 
to contribute to insulin resistance in Type 2 Diabetes. However, the major contributors to insulin 
resistance in A-T patients caused by the disruption of their ATM-p53 signaling pathway are still 
not fully understood. In this project, the p53Ser23Ala mouse model in which ATM-p53 signaling 
pathway was interrupted at the p53 phosphorylation site Serine 23 was utilized to investigate the 
insulin signaling pathway.  
 Through Immunoblot results, the effect due to the interruption of the ATM-p53 on the 
insulin signaling pathway was demonstrated. It was found that the insulin signaling pathway was 
impaired in the fibroblasts and liver tissue of the p53Ser23Ala mice, however still remained 
active in their muscle tissue. Typically, Type 2 diabetes is characterized by insulin resistance in 
the certain types of tissue, including liver, adipose, and muscle tissue. Since the defect in the 
insulin transduction pathway was only observed in fibroblasts and liver tissue, it could be 
concluded that the mutation at the phosphorylation site Serine 23 just leads to tissue-specific 
insulin resistance. 
 As the results the Immunoblots implicated the evidence and characterization of insulin 
resistance in p53Ser23Ala mice, the factors leading to insulin resistance in the fibroblasts and 
liver tissue were then investigated using quantitative Real-Time PCR. The gene expression of 
pro-inflammatory cytokines, though was found to be elevated, but only significantly in the 
fibroblasts. Additionally, the expression of p53-dependent antioxidant genes (Sesn 1, 2, and 3) in 
the fibroblasts of p53Ser23Ala mice, one factor that is balanced against the ROS levels, has been 
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found to be significantly downregulated, indicating the potential for increased ROS levels in 
these mice. Increased ROS levels, which has been believed to primarily account for A-T 
patients’ clinical pathologies (Barlow et al., 1999, Watter, 2003), have been also attributed as 
one of underlying mechanisms for insulin resistance in Type 2 diabetes. Furthermore, as p53 
protein is the downstream effector in the ATM-p53 pathway, these results indicate that the p53-
regulated Sestrin antioxidant gene expression is the main contributor to insulin resistance in 
p53Ser23Ala mice.  
 Previous study from Sluss Lab also found that loss of antioxidant gene expression in the 
p53Ser18Ala mouse model associates with insulin resistance. As it is the same factor that was 
found in both p53Ser18Ala and p53Ser23Ala mouse models, it is believed that antioxidant 
therapy could be the potential treatment to restore the insulin sensitivity in A-T patients. Further 
experiments should include Immunoblots on p53Ser23 mice on antioxidant diet to check whether 
their insulin signaling pathway is restored or not to confirm the conclusion. The expression of 
antioxidant genes on the liver tissue should also be examined. Other factors that might lead to 
excess ROS levels or have been proposed as underlying mechanism for insulin resistance in 
Type 2 Diabetes should also be monitored.  
In conclusion, these findings implicate that the both of ATM-mediated phosphorylation 
sites on p53 at Serine18 and Serine 23 play an important role in insulin resistance by regulating 
the expression of antioxidant genes. They also highlight the emerging role of p53 in metabolic 
diseases, not just their traditional role as the tumor suppressor protein.  
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Figures 
 
Figure 6: The relative expression in WT and p53Ser23Ala MEFs of Sesn1, 2, and 3 (A); 
TNF-α and IL-6 (B); mGhrl (C). Relative expression between WT vs. p53Ser23Ala mice was 
measured by quantitative Real-Time PCR analysis.  The amount of Gapdh mRNA in each 
sample was used to calculate relative mRNA expression (means ± SEM, n=3). Statistically 
significant differences between WT and p53Ser23Ala mice are indicated (*, p < 0.05). (A) The 
levels of Sestrin antioxidant gene expression in p53Ser23Ala mice were significantly reduced 
compared to those of WT mice (B) The levels of inflammatory gene expression, including TNF-
α and IL-6 were significantly increased in the MEFs of p53Ser23Ala mice compared to those of 
WT mice (C) The gene expression of Ghrl, a growth-hormone stimulator, was significantly 
downregulated in the MEFs of p53Ser23 mice compared to that of WT mice.  
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 Figure 7: The relative expression in WT and p53Ser23Ala livers of TNF-α, IL-6, and IL-1 
Relative expression between WT vs. p53Ser23Ala mice was measured by quantitative Real-Time 
PCR analysis.  The amount of Gapdh mRNA in each sample was used to calculate relative 
mRNA expression (means ± SEM, n=9). Statistically significant differences between WT and 
p53Ser23Ala mice are indicated (*, p < 0.05). The levels of inflammatory gene expression, 
including TNF-α and IL-6 were significantly increased in the p53Ser23Ala mice compared to 
WT mice, indicating increased inflammatory signaling in p53Ser23Ala liver. 
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Figure 8: (A) Immunoblots for MEFs Time Course Insulin Treatment examining 
investigating AKT phosphorylation in WT and p53Ser23Ala mice using anti-pSer473 AKT, 
anti-pThr308 AKT, anti AKT. The first and second panels showed the defect in the insulin 
signaling pathway. The bands of p53Ser23Ala mice at 0.5 hour and 1 hour time points were 
fainter compared to WT mice. The third panel presented equal loading. (B) Quantification of 
AKT Activation from Immunoblots using anti-pThr308 AKT. Not as much AKT was 
activated in p53Ser23Ala mice compared to WT mice. The difference in the activation of AKT 
between WT and p53Ser23Ala MEFs at 1 hour time point the treatment was significantly greater 
compared to the difference in the activation of AKT between WT and p53Ser23Ala mice at 0 
hour time point (*, p<0.05) 
*
0.0
200000.0
400000.0
600000.0
800000.0
1000000.0
1200000.0
1400000.0
1600000.0
0 0.5 1 4
Re
la
tiv
e 
AK
T 
Ac
tiv
at
io
n 
 
Time (hour)
AKT Activation in MEFs
WT
p53Ser23Ala
-pSer473 AKT 
 -pThr308 AKT 
 - AKT 
 
Time in hours 
 
MEFs 
WT 
 
p53Ser23Ala 
Con  0.5  1    4   Con  0.5   1   4 
30 
 
(A)  
 
 
    
 
 
  
 
(B)       
 
 
   
 
 
 
 
Figure 9:  Immunoblots for Liver (A) and Muscle (B) investigating AKT phosphorylation in 
WT and p53Ser23Ala mice. Extracts from livers and muscle of wild-type and p53Ser23Ala 
mice were examined by Immunoblot analysis using anti-pSer473 AKT, anti-pThr308 AKT, and 
anti-AKT antibodies. (A) In the upper panels, in the absence of insulin, AKT was not activated 
for both wild type and p53Ser23Ala liver tissues. However, in response to insulin treatment, the 
signals for wild type tissues were stronger than those of p53Ser23Ala tissues, indicating insulin 
resistance in the liver tissue. Equal loading of AKT was shown in the lower panels. (B) The 
upper and middle panels demonstrated that there was no difference in AKT phosphorylation 
between the wild type and p53Ser23Ala muscle tissue. AKT was activated in the muscle of both 
genotypes in response to insulin. Equal loading of AKT was presented in the lower panels. 
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